QuidelOrtho Launches Certified Analyzer Program
QuidelOrtho (NYSE:QDEL) has launched its Certified Analyzer Program, aimed at expanding access to diagnostic testing in rural and community hospitals across the United States. The initiative focuses on healthcare facilities with fewer than 100 beds, offering certified VITROS� analyzers at reduced costs.
The program features certified VITROS XT 7600, 5600 Integrated Systems, and VITROS 3600 Immunodiagnostic System. Each analyzer undergoes a rigorous certification process including over 140 system checks, hardware maintenance, and performance testing at QuidelOrtho's Rochester facility. The certified analyzers come with a 12-month warranty on service and support.
QuidelOrtho (NYSE:QDEL) ha lanciato il suo Certified Analyzer Program, volto ad ampliare l'accesso ai test diagnostici negli ospedali rurali e comunitari degli Stati Uniti. L'iniziativa si concentra su strutture con meno di 100 posti letto, offrendo analizzatori VITROS� certificati a costi ridotti.
Il programma include gli analizzatori certificati VITROS XT 7600, 5600 Integrated Systems e VITROS 3600 Immunodiagnostic System. Ciascun analizzatore è sottoposto a un rigoroso processo di certificazione che comprende oltre 140 controlli del sistema, manutenzione hardware e test di performance presso la struttura di QuidelOrtho a Rochester. Gli analizzatori certificati sono coperti da una garanzia di 12 mesi su servizio e supporto.
QuidelOrtho (NYSE:QDEL) ha lanzado su Certified Analyzer Program, dirigido a ampliar el acceso a pruebas diagnósticas en hospitales rurales y comunitarios de Estados Unidos. La iniciativa se centra en centros con menos de 100 camas, ofreciendo analizadores VITROS� certificados a un costo reducido.
El programa incluye los analizadores certificados VITROS XT 7600, 5600 Integrated Systems y VITROS 3600 Immunodiagnostic System. Cada analizador pasa por un riguroso proceso de certificación que incluye más de 140 comprobaciones del sistema, mantenimiento de hardware y pruebas de rendimiento en las instalaciones de QuidelOrtho en Rochester. Los analizadores certificados cuentan con una garantÃa de 12 meses para servicio y soporte.
QuidelOrtho (NYSE:QDEL)ê°€ 미êµì� ë†ì´Œ ë°� ì§€ì—� 병ì›ì—서 진단 ê²€ì‚� ì ‘ê·¼ì„±ì„ í™•ëŒ€í•˜ê¸° 위해 Certified Analyzer Programì� 시작했습니다. ì� í”„ë¡œê·¸ëž¨ì€ 100ë³‘ìƒ ë¯¸ë§Œì� ì˜ë£Œê¸°ê´€ì� 대ìƒìœ¼ë¡� 하며, ì¸ì¦ë� VITROSâ„� ë¶„ì„기를 í• ì¸ë� 비용으로 ì œê³µí•©ë‹ˆë‹�.
프로그램ì—는 ì¸ì¦ë� VITROS XT 7600, 5600 Integrated Systems, VITROS 3600 Immunodiagnostic Systemì� í¬í•¨ë©ë‹ˆë‹�. ê°� ë¶„ì„기는 QuidelOrthoì� 로체스터 시설ì—서 140ê°� ì´ìƒì� 시스í…� ì ê²€, 하드웨어 ì •ë¹„ ë°� 성능 테스트를 í¬í•¨í•� 엄격í•� ì¸ì¦ ì ˆì°¨ë¥� 거칩니다. ì¸ì¦ë� ë¶„ì„기는 서비ìŠ� ë°� ì§€ì›ì— 대í•� 12개월 ë³´ì¦ì� ì œê³µë©ë‹ˆë‹�.
QuidelOrtho (NYSE:QDEL) a lancé son Certified Analyzer Program, destiné à élargir l'accès aux tests diagnostiques dans les hôpitaux ruraux et communautaires des États-Unis. L'initiative cible les établissements de moins de 100 lits, proposant des analyseurs VITROS� certifiés à un coût réduit.
Le programme comprend les analyseurs certifiés VITROS XT 7600, 5600 Integrated Systems et VITROS 3600 Immunodiagnostic System. Chaque analyseur suit un processus de certification strict incluant plus de 140 contrôles du système, la maintenance matérielle et des tests de performance dans les installations de QuidelOrtho à Rochester. Les analyseurs certifiés bénéficient d'une garantie de 12 mois couvrant le service et l'assistance.
QuidelOrtho (NYSE:QDEL) hat sein Certified Analyzer Program gestartet, mit dem Ziel, den Zugang zu diagnostischen Tests in ländlichen und kommunalen Krankenhäusern in den Vereinigten Staaten zu erweitern. Die Initiative richtet sich an Einrichtungen mit weniger als 100 Betten und bietet zertifizierte VITROS�-Analyzersysteme zu reduzierten Kosten an.
Zum Programm gehören die zertifizierten VITROS XT 7600, 5600 Integrated Systems und VITROS 3600 Immunodiagnostic System. Jeder Analyzer durchläuft einen strengen Zertifizierungsprozess mit über 140 Systemprüfungen, Hardware-Wartung und Leistungstests in QuidelOrthos Einrichtung in Rochester. Auf die zertifizierten Analyzer gibt es eine 12-monatige Garantie für Service und Support.
- Program expands access to diagnostic testing in underserved communities
- Comprehensive certification process with over 140 system checks ensures reliability
- 12-month warranty included for service and support
- Cost-effective solution for smaller healthcare facilities
- None.
Initiative to expand testing access to underserved
"Our mission is rooted in equipping our customers so they can deliver diagnostic excellence to patients," said , Senior Vice President,
Each analyzer in the program undergoes a robust, multi-point certification process at QuidelOrtho's Rochester facility, including over 140 system checks, functional adjustments, hardware cleaning or replacement, and extensive performance testing. These analyzers undergo a comprehensive certification process to align with QuidelOrtho's established quality and performance criteria and include a 12-month warranty on service and support.
The program features certified VITROS XT 7600 and 5600 Integrated Systems and the VITROS 3600 Immunodiagnostic System. The VITROSÂ platforms are designed to support community labs running general chemistries, immunoassay tests and drugs of abuse screening.
"We're proud to support healthcare providers who are the backbone of their communities, backed by our award-winning service and top-ranked customer satisfaction," added Jones. "This program isn't just about affordability; it's designed to improve accessibility and access of diagnostic solutions for healthcare providers in underserved communities."
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit  and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.Â
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed–from home to hospital, lab to clinic.
Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions.
Investor Contact: Juliet Cunningham Vice President, Investor Relations | Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications |
View original content to download multimedia:
SOURCE QuidelOrtho Corporation